

DAFTAR PUSTAKA

- 1 Christine Ann Caneba. Ovarian cancer metabolism : effect of anoikis condition and nitric oxide on ovarian cancer metabolism, and effect of metabolites on ovarian cancer migration (thesis). Texas:Rice University. 2013.
- 2 I B Upadana Permana. Karakteristik pasien kanker ovarium di Rumah Sakit Dr. H. Abdul Moeloek Bandar Lampung Tahun 2009-2013. E-Jurnal Medika UNILA. 2015; 5(9):43-47.
- 3 GLOBOCAN (2018). Cancer Incidence and mortality worldwide. <https://gco.iarc.fr/> - Diakses Oktober 2018.
- 4 American Cancer Society (2018). Cancer facts and figures 2018. GA; American Cancer Society. <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf> - diakses Oktober 2018
- 5 Hacker NF, Moore JG, Gambone JC. Essentials of obstetrics and gynecology. 4th ed. Philadelphia : Elsevier Saunders; 2004.
- 6 Hurt KJ, Guile MW, Bienstock JL, Fox HE, Wallach EE. The john hopkins manual of gynecology dan obstetrics. 4th ed. Philadelphia : Wolters Kluwer; 2011.
- 7 Razi S, Ghoncheh M, Mohammadian-Hafshejani A, Aziznejhad H, Mohammadian M, Salehiniya H. The incidence and mortality of ovarian cancer and their relationship with the human development index in asia. E Can Med Science. 2016 ; 10: 628.
- 8 Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Can Bio & Med. 2017; 14(1): 9–32.
- 9 Dhitayoni IA, Budiana ING. Profil pasien kanker ovarium di rumah sakit umum pusat sanglah denpasar – bali periode juli 2013 – juni 2014. E-Jurnal Medika. 2017;Vol 6.
- 10 Ersnt L. Ovarian cancer development and metastasis. The American J of Pathology. 2010 ; 177(3): 1053–1064.
- 11 Yeung TL, Leung CS, Yip KP, Yeung CLA, Wong STC, Mok SC. Cellular and molecular processes in ovarian cancer metastasis. A review in the theme: cell and molecular processes in cancer metastasis. America Physio Soc. 2015; 309(7): C444–C456.
- 12 Sehouli J, Senyuva F, Fotopoulou C, Neumann U, Denkert C, Werner L et al. Intra-Abdominal Tumor Dissemination Pattern and Surgical Outcome in 214 Patients With Primary Ovarian Cancer. J Surg Oncol. 2009;99:424–427.
- 13 Puiffe ML, Page CL, Filaili-Mouhim A, Ziertarska M, Ouellet V, Tonin PN, et al. Characterization of ovarian cancer ascites on cell Invasion, proliferation, spheroid formation, and gene expression in an *in vitro* model of epithelial ovarian cancer. Elsevier. 2007; 9(10): 820–829.

- 14 Shen-Ghunter J, Mannel RS. Ascites as a predictor of ovarian malignancy. *Gynecol Oncol.* 2002;87(1):77-83.
- 15 Indang T, Dieta N. Analisis Ketahanan Hidup Lima Tahun Penderita Kanker Ovarium Epithelial di Rumah Sakit Dharmais Jakarta. Jakarta : Jurnal Kesehatan Masyarakat Nasional, 2010, Vol. 5.
- 16 Kipps E, Tan DSP, Kaye SB. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. *Europe Pubmed Cent.* 2013;13(4): 273-282.
- 17 Herr D, Sallmann A, Bekes I, Konrad R, Holzheu I, Kreienberg R, Wulff C. VEGF induces ascites in ovarian cancer patients via increasing peritoneal permeability by downregulation of Claudin 5. *Gynecol Oncol.* 2012;127(1):210-6.
- 18 Bekes I, Friedl TW, Kohler T, Mobus V, Janni W, Wockel A, Wulff C. Does VEGF facilitate local tumor growth and spread into the abdominal cavity by suppressing endothelial cell adhesion, thus increasing vascular peritoneal permeability followed by ascites production in ovarian cancer?. *Mol Cancer.* 2016;15:13.
- 19 Worzfeld T, Strandmann EPV, Huber M, Adhikary T, Wagner U, Reinartz S, et al. The Unique Molecular and Cellular Microenvironment of Ovarian Cancer. *Frontiers In Onc.* 2017; 7: 24.
- 20 Auer K, Bachmayr-Heyda A, Aust S, Sukhbaatar N, Reiner AT, Grimm C, et al. Peritoneal tumor spreads in serous ovarian cancer-epithelial mesencymal status and outcome. *Oncotarget.* 2015; 6(19): 17261–17275.
- 21 Luo Z, Wang Q, Lau WB, Lau B, Xu L, Zhao L, et al. Tumor microenvironment: The culprit for ovarian cancer metastasis?. *Cancer Lett.* 2016;377(2):174-82.
- 22 Sahin H, Meydanli MM, Sari ME, Yalcin I, Coban G, Ozkan NT, et al. Does the primary route of spread have a prognostic significance in stage III non-serous epithelial ovarian cancer?. *J Ovarian Res.* 2018;11(1):21.
- 23 Pradeep S, Kim SW, Wu SY, Nishimura M, Chaluvally-raghavan P, Miyake T *et al.* Hematogenous metastasis of ovarian cancer: rethinking mode of spread. *HHS Public Access.* 2014; 26(1): 77–91.
- 24 Thorchiaro E, Lorezanto A, Olivero M, Valdembri D, Gagliardi PA, Marta G *et al.* Peritoneal and hematogenous metastases of ovarian cancer cells are both controlled by the p90RSK through a self-reinforcing cell autonomous mechanism. *Oncotarget.* 2016; 7(1): 712–728.
- 25 Paulsen F, Waschke J. Sobotta Jilid 2. Edisi 23. Jakarta:EGC; 2010.
- 26 Snell RS. *Clinical Anatomy by Regions - 9th ed.* Philadelphia:Lippincott Williams & Wilkins, a Wolters Kluwer business; 2012.
- 27 Seebacher V, Aust S, D'Andrea D, Grimm C, Raiser E, Tiringner D, et al. Development of a tool for prediction of ovarian cancer in patients with adnexal masses: value of plasma. *pLoS One.* 2017;12(8):e0182383.
- 28 Cho KR, Shih LM. Ovarian Cancer. *Annu Rev Pathol.* 2009 ;4:287-313.
- 29 Aziz MF, Andrijono, Saifuddin AB. *Onkologi ginekologi .Edisi pertama.* Jakarta : Yayasan Bina Pustaka Sarwono Prawirohardjo; 2006.

- 30 Anwar M, Baziaz A, Prabowo RP. Ilmu kandungan. Edisi ketiga. Jakarta: PT Bina Pustaka Sarwono Prawirohardjo; 2011.
- 31 Schuiling KD, Likis FE. Woman's gynecologic health. 2nd ed. United States America : Jones & Bartlett Learning; 2013.
- 32 Simamora RPA, Hanriko R, Sari RDP. Hubungan Usia, Jumlah Paritas, dan Usia Menarche Terhadap Derajat Histopatologi Kanker Ovarium Di RSUD Dr.H.Abdul Moeloek Bandar Lampung Tahun 2015-2016. E-jurnal Medika UNILA;2018.
- 33 Cibula D, Gompel A, Mueck AO, La Vecchia C, Hannaford PC, Skouby SO, et al. Hormonal contraception and risk of cancer.Hum Reprod Update. 2010;16(6):631-50.
- 34 McLemore MR, Miaskowski C, Aouizerat BE, Chen L, Dodd MJ. Epidemiologic and genetic factors associated with ovarian. HHS Public Access. 2009; 32(4): 281–290.
- 35 Savant SS, Sriramkumar S, O'Hagan HM. The Role of Inflammation and Inflammatory mediators in the development, progression, metastasis, and chemoresistance of epithelial ovarian cancer. Cancers (Basel). 2018; 10(8): 251.
- 36 Purdie DM, Bain CJ, Siskind V, Webb PM, Green AC. Ovulation and risk of epithelial ovarian cancer. Int J Cancer. 2003;104(2):228-32.
- 37 Budiana ING, Peran klinis ca-125 pada kanker ovarium. E-Jurnal Medika UNUD; 2014.
- 38 Berek JS. Berek & novak's gynecology. 14th ed. Philadelphia (PA): Wolters Kluwer; 2007.
- 39 Berek JS. Lymph node-positive stage IIIC ovarian cancer: a separate entity?. Int J Gynecol Cancer. 2009;19 Suppl 2:S18-20.
- 40 Green AE, Garcia AA, Ahmed S. Ovarian cancer. Medscape; 2018.
- 41 Hacker NF, Moore JG, Gambone JC. Essentials of obstetrics and gynecology. 4th ed. Philadelphia (PA); Elsevier Saunders; 2004.
- 42 Foti PV, Attina G, Spadola S, Caltabiano R, Farina R, Palmucci S, et al. MR imaging of ovarian masses: classification and differential diagnosis. Insight Imaging. 2016;7(1):21-41.
- 43 Doubeni CA, Doubeni AR, Myers AE. Diagnosis and management of ovarian cancer. An Fam Physician. 2016;93(11):937-44.
- 44 Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. 2013; 24 (Suppl 6): vi24-vi32.
- 45 Ahmed N, Stenvers KL. Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research. Front Oncol. 2013; 3: 256.
- 46 Martin-Hirsch P, Preston N, Tomlinson A. Management of ascites in ovarian cancer patients. Scientific impact paper No.45. Royal Collage of Obs&Gyn;2014.
- 47 Cohen M, Petignat P. The bright side of ascites in ovarian cancer. Cell Cycle. 2014; 13(15): 2319.

- 48 Tirkes T, Sandrasegaran K, Patel AA, Hollar MA, Tejada JG, Tann M, et al. Peritoneal and retroperitoneal anatomy and its relevance for cross-sectional imaging. *Radiographics*. 2012; 32(2):437-51.
- 49 Tortora GJ, Derrickson B. Principles of anatomy and physiology. United States of America:John Wiley & Son Inc; 2012..
- 50 Fagotti A, Gallota V, Romano F, Fanfani F, Rossito C, Naldini A, et al. Peritoneal carcinosis of ovarian origin. *World J Gastrointest Oncol*. 2010; 2(2): 102–108.
- 51 Healy JC. Detection of peritoneal metastases. *Cancer Imaging*. 2015; 1(2): 4–12.
- 52 Suastrri NMP. Pemeriksaan radiologi untuk deteksi kanker ovarium. *Kalbemed*;2018.
- 53 Nagell JRV, Hoff JT. Transvaginal ultrasonography in ovarian cancer screening: current perspectives. *Int J Womens Health*. 2014; 6: 25–33.
- 54 Jin YR, Yang XL, Li QQ, Yan ZL, Yang HY, Liao C. CT of ovarian cancer: 3D ciematic rendering for preoperative evaluation. *J Ovarian Res*. 2018;11(1):86.
- 55 Sahdev A. CT in ovarian cancer staging: how to review and report with emphasis on abdominal and pelvic disease for surgical planning. *Cancer Imaging*. 2016; 16: 19.
- 56 Sangisetty SL, Miner TJ. Malignant ascites: A review od prognostic factors, pathophysiology and therapeutic measures. *World J Gastrointest Surg*. 2012; 4(4):87-95.
- 57 Worzfeld T, Pogge von Strandmann E, Huber M, Adhikary T, Wagner U, Reinartz S, et al. The Unique Molecular and Cellular Microenvironment of Ovarian Cancer. *Front Oncol*. 2017 ;7:24.
- 58 Klymenko Y, Kim O, Loughran E, Yang J, Lombard R, Alber M, et al. Cadherin composition and multicellular aggregate invasion in organotypic models of epithelial ovarian cancer intraperitoneal metastasis. *Oncogene*. 2017;36(42):5840-5851.
- 59 Meunier L, Puiffe M, Page CL, Filali-Mouhin A, Chevrette M, Tonin PN, et al. Effect of Ovarian Cancer Ascites on Cell Migration and Gene Expression in an Epithelial Ovarian Cancer In Vitro Model. *Trans Oncol*. 2010; 3(4): 230–238.
- 60 Masoumi MS, Amini A, Morris DL, Pourgholami MH. Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer. *Cancer Metastasis Rev*. 2012;31(1-2):143-62.
- 61 Gea IT, Loho MF, Wagey FW. Gambaran jenis kanker ovarium di RSUP Prof. Dr. R.D. kandou manado periode januari 2013 - desember 2015. *Jurnal eCl*. 2016; Volume 4, Nomor 2.
- 62 Fuh KC, Shin JY, Kapp DS, Brooks RA, Ueda S, Urban RR et al. Survival differences of asian and caucasian epithelial ovarian cancer patients in the united states. *Gynecol Oncol*. 2015 ;136(3):491-7.
- 63 Karst AM, Drapkin R. The new face of ovarian cancer modeling: better prospects for detection and treatment. *F 1000 Med Rep*. 2011 ;3:22.

- 64 Huang H, Li YJ, Lan CY, Huang QD, Feng YW, Huang YW et al. Clinical significance of ascites in epithelial ovarian cancer. *Neoplasma*. 2013; 60(5):546-52.
- 65 Szender JB, Emmons T, Bellioti S, Dickson D, Khan A, Morrel K et al. Impact of ascites volume on clinical outcomes in ovarian cancer: a cohort study. *Gynecol Oncol*. 2017; 146(3):491-497.
- 66 Ruangruang B, Miller A, Richard SD, Hamilton CA, Rodriguez N, Bookman MA. Should stage IIIC ovarian cancer be further stratified by intraperitoneal vs. retroperitoneal only disease?: a gynecologic oncology group study. *Gynecol Oncol*. 2012; 124(1):53-8.

